lamictal 25 mg chewable/disp. tabl.
glaxosmithkline pharmaceuticals sa-nv - lamotrigine 25 mg - chewable/dispersible tablet - 25 mg - lamotrigine 25 mg - lamotrigine
lamictal 100mg dispersible tablets
pharmaram ltd - lamotrigine - dispersible tablet - 100mg
lamictal 200 mg dispersible chewable tablets
imbat limited - lamotrigine - dispersible tablet - 200 milligram(s) - other antiepileptics; lamotrigine
lamictal 50mg dispersible/chewable tablet
imbat limited - lamotrigine - dispersible tablet - 50 milligram(s) - other antiepileptics; lamotrigine
lamictal 100 mg dispersible/chewable tablets
imbat limited - lamotrigine - dispersible tablet - 100 milligram(s) - other antiepileptics; lamotrigine
lamictal 25mg dispersible/chewable tablets
imbat limited - lamotrigine - dispersible tablet - 25 milligram(s) - other antiepileptics; lamotrigine
lamictal dispersible tablet 2 mg
glaxosmithkline pte ltd - lamotrigine - tablet, film coated - 2 mg - lamotrigine 2 mg
lamictal tablet 25 mg
glaxosmithkline pte ltd - lamotrigine - tablet - 25.0 mg - lamotrigine 25.0 mg
lamictal tablets chewable/dispersible
glaxosmithkline pharmaceuticals s.a. - lamotrigine - tablets chewable/dispersible - 2mg
lamictal lamotrigine 25 mg dispersible/chewable tablet bottle
aspen pharmacare australia pty ltd - lamotrigine, quantity: 25 mg - tablet - excipient ingredients: povidone; hyprolose; calcium carbonate; aluminium magnesium silicate; sodium starch glycollate; magnesium stearate; saccharin sodium; flavour - lamictal is an anti-epileptic drug for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamictal used initially as ?add-on? therapy. the use of lamictal has also been found to be effective as monotherapy following withdrawal of concomitant anti-epileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see clinical trials). lamictal is indicated for the prevention of depressive episodes in patients with bipolar disorder.